|Videos|January 26, 2022
Urology Times 50 Innovations Series: Tissue engineering and regenerative medicine
Author(s)Urology Times staff
"These are fairly new technologies, but they've already made a dent into patient care," says Anthony Atala, MD.
Advertisement
As part of the Urology Times' 50th Anniversary Innovation Celebration, Anthony Atala, MD, discusses how tissue engineering and regenerative medicine have greatly impacted the field of urology over the past 50 years. Atala is a director of the Wake Forest Institute for Regenerative Medicine, and the W. Boyce Professor and Chair of Urology at Wake Forest University in Winston-Salem, North Carolina.
Advertisement
Related to this article
Sandip M. Prasad, MD, MPhil, discusses the safety profile of mitomycin intravesical solution, including common adverse events and patient counseling during chemoablation for NMIBC.
These FAQs outline key recommendations and practical takeaways from the AUA/SUFU/AUGS Genitourinary Syndrome of Menopause guideline.
Sandip M. Prasad, MD, MPhil, discusses 3-year ENVISION trial data showing durable responses with mitomycin intravesical solution for recurrent LG-IR-NMIBC.
Armine K. Smith, MD, discusses sexual health counseling, sex-specific considerations, and organ-preserving approaches for patients undergoing radical cystectomy.
This approval expands the label for nogapendekin alfa inbakicept to include patients with high-grade papillary-only tumors.
Melissa Hadley Barrett discusses real-world outcomes and tolerability of intranasal vardenafil for men with persistent erectile dysfunction despite prior standard therapy.
The completion of the first procedure marks the beginning of a controlled US commercial release.
Delayed diagnosis and skipped nodal staging worsen penile cancer outcomes, according to Luis G. Medina, MD.
Advertisement
Advertisement
Trending on Urology Times
1
Study assesses real-world outcomes with intranasal vardenafil for ED
2
Urocross Expander System enters US commercial use for symptomatic BPH
3
Three-year data show durable responses with mitomycin intravesical solution
4
FAQs: The AUA 2025 Guideline on Genitourinary Syndrome of Menopause
5